Yesterday HHS Sec. Azar announced the @US_FDA has completed its review of the IND application for mRNA-1273 our potential vaccine for SARS-CoV-2 &amp; allowed it to proceed to clinic. On Feb. 24 the 1st clinical batch of mRNA-1273 was shipped to NIH for use in the Phase 1 study.